Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) PT at $11.57

Rezolute, Inc. (NASDAQ:RZLT) has been given an average rating of “Buy” by the seven brokerages that are covering the company, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $11.57.

Several analysts have recently weighed in on RZLT shares. BTIG Research boosted their target price on Rezolute from $13.00 to $15.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Guggenheim started coverage on Rezolute in a report on Tuesday, August 27th. They issued a “buy” rating and a $11.00 target price for the company. Maxim Group boosted their target price on Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. JMP Securities reissued a “market outperform” rating and issued a $7.00 target price on shares of Rezolute in a report on Friday, September 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Rezolute in a report on Friday, September 27th.

Rezolute Price Performance

Shares of NASDAQ RZLT opened at $4.70 on Monday. The company has a market capitalization of $188.63 million, a price-to-earnings ratio of -4.12 and a beta of 1.19. The business has a 50-day moving average of $4.68 and a two-hundred day moving average of $4.05. Rezolute has a 1 year low of $0.72 and a 1 year high of $6.10.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14). As a group, equities research analysts expect that Rezolute will post -1.23 earnings per share for the current year.

Institutional Trading of Rezolute

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jeppson Wealth Management LLC purchased a new stake in Rezolute during the 2nd quarter valued at approximately $45,000. Virtu Financial LLC purchased a new position in shares of Rezolute during the 1st quarter worth approximately $37,000. XTX Topco Ltd raised its stake in shares of Rezolute by 205.8% during the 2nd quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after buying an additional 22,660 shares in the last quarter. Cubist Systematic Strategies LLC raised its stake in shares of Rezolute by 366.0% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock worth $233,000 after buying an additional 42,597 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Rezolute during the 2nd quarter worth approximately $255,000. 82.97% of the stock is owned by hedge funds and other institutional investors.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.